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Available online 28 April 2008The aimof the present studywas to identify gene polymorphisms that confer susceptibility to obesity. A total of
5448 unrelated Japanese individuals from two independent populations were examined: subject
panel A comprised 4252 individuals who visited participating hospitals; subject panel B comprised 1196
community-dwelling elderly individuals. The genotypes for 95 polymorphisms of 67 candidate genes were
determined. Theχ2 test revealed that six polymorphismswere related (pb0.05) to the prevalence of obesity in
subject panel A; after application of Bonferroni's correction, however, only the 2677G → A/T polymorphism
(rs2032582) of the ATP-binding cassette, subfamily B, member 1 gene (ABCB1) was signiﬁcantly associated
(p=0.0003)with obesity. Subsequent multivariable logistic regression analysis also revealed that the 2677G→
A/T polymorphism of ABCB1 was signiﬁcantly associated with obesity. For validation of this association, the
2677G → A/T polymorphism of ABCB1 was examined in subject panel B and again found to be signiﬁcantly
associated with obesity. Body mass index was signiﬁcantly (p=0.01) greater for individuals with the variant
T allele of this polymorphism than for thosewith the GG genotype in the combined subject panels A and B. Our
results suggest that the ABCB1 genotype may prove informative for assessment of genetic risk for obesity in
Japanese individuals.
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Obesity
Polymorphism
Genetics
Body mass index
ABCB1Obesity has become a major public health problem as a result of its
increasing prevalence in most developed countries. The World Health
Organization (WHO) estimates that ~1.6 billion adults were over-
weight [body mass index (BMI)≥25 kg/m2] and at least 400 million
adults were clinically obese (BMI≥30 kg/m2) worldwide in 2005 [1].
WHO further predicts that ~2.3 billion adults will be overweight and
more than 700 million will be obese by 2015. Obesity is associated
with cardiovascular morbidities, including hypertension and athero-
sclerosis [2]. Adipose tissue constitutes a major endocrine system that
secretes a variety of bioactive substances termed adipocytokines.
Recent studies have shown that altered adipocytokine secretion
proﬁles increase the risk of obesity-related cardiovascular disorders
[3,4]. The interaction of environmental factors, such as behavior
(overeating and physical inactivity) and socioeconomic conditions,
affects an individual's risk for obesity [5]. Obesity also results from the
effects of multiple genetic factors. The identiﬁcation of susceptibilityl rights reserved.genes for obesity is therefore important for its prediction and for
potential intervention to avert future cardiovascular events.
Numerous epidemiological studies performed in different popula-
tions (twin and familial aggregation studies) have recognized the
contribution of genetic factors to individual susceptibility to obesity
[6]. Whole-genome scans have identiﬁed several chromosomal
regions that are linked to obesity [7–9]. Association studies have
also identiﬁed genes related to obesity. For example, a Trp64Arg poly-
morphism of the β3-adrenergic receptor gene (ADRB3) was associated
with obesity [10], but only about half of the various studies that
attempted to replicate this ﬁnding did so. An Arg16Gly polymor-
phism of the β2-adrenergic receptor gene (ADRB2) and a Pro115Gln or
Pro12Ala polymorphism of the peroxisome proliferator-activated
receptor-γ2 gene (PPARG2) have also each been shown to be asso-
ciated with morbid obesity [11–13]. More recently, a genome-wide
association study of obesity-related traits showed that a polymor-
phism (rs9930506) of the fat mass- and obesity-associated gene
(FTO) was markedly associated with BMI, hip circumference, and body
weight [14]. Variation in FTO was also found to contribute to
childhood and adult obesity in various populations [15,16]. The
genome-wide association study has become a standard approach to
Table 1
Characteristics of the 5448 study subjects
Characteristic Subject panel A Subject panel B
Obesity Controls p Obesity Controls p
No. of subjects 1308 2944 312 884
Age (years) 62.8±
10.5
65.8±
11.2
b0.0001 70.1±
3.64
71.2±
5.11
0.0003
Sex
(male/female, %)
58.4/
41.6
60.4/
39.6
0.2238 44.9/
55.1
49.6/
50.4
0.1550
Current or former
smoker (%)
21.2 20.0 0.3823 31.1 30.3 0.7990
BMI (kg/m2) 27.42±
2.28
21.81±
2.09
b0.0001 26.99±
1.80
21.80±
2.07
b0.0001
Systolic BP
(mm Hg)
144±25 142±26 0.0109 138±17 133±18 b0.0001
Diastolic BP
(mm Hg)
78±14 76±15 0.0004 81±10 78±11 0.0003
Total cholesterol
(mmol/L)
5.33±
1.04
5.13±
1.01
b0.0001 5.16±
0.89
5.10±
0.84
0.3026
Triglycerides
(mmol/L)
1.81±
1.52
1.47±
1.04
b0.0001 1.86±
1.07
1.51±
0.91
b0.0001
HDL-cholesterol
(mmol/L)
1.27±
0.37
1.37±
0.40
b0.0001 1.39±
0.35
1.54±
0.39
b0.0001
FPG (mmol/L) 6.91±
3.25
6.68±
3.22
0.0413 6.91±
2.01
6.62±
1.73
0.0179
Smoker, smoking of ≥10 cigarettes daily. BP, blood pressure; FPG, fasting plasma glucose.
Data are means±SD.
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diseases. However, the candidate gene approach remains important
for the identiﬁcation of such genes when the candidate genes are
appropriately selected [17]. The genetic basis of obesity as a composite
phenotype remains to be demonstrated deﬁnitively, likely because
obesity is amultifactorial disorder and a large number of susceptibility
genes may contribute to its pathogenesis. Large numbers of potential
associations therefore need to be examined to identify gene poly-
morphisms suitable for prediction of the risk for common complex
disorders such as obesity.
We have now performed a large-scale association study for 95
candidate gene polymorphisms and obesity in 5448 unrelated
Japanese individuals from two independent populations. The aim of
the present study was to identify gene polymorphisms that confer
susceptibility to obesity and thereby to contribute to the personalized
prevention of this condition.
Results
Characteristics of study subjects
The characteristics of subject panels A and B are shown in Table 1.
For subject panel A, BMI, systolic and diastolic blood pressure, the
serum concentrations of total cholesterol and triglycerides, and the
fasting plasma glucose level were greater, whereas age and the serum
concentration of high-density lipoprotein-cholesterol were lower, inTable 2
Polymorphisms related (pb0.05) to obesity in subject panel A as revealed by the χ2 test an
Gene symbol Locus Polymorphism
dbSNP
ABCB1 7q21.1 2677G → A/T (Ala893Thr/Ser) rs2032
CD40LG Xq26 −3459 A→ G rs3092
CYP3A5 7q22.1 6986A → G in intron 3 rs77674
MMP9 20q11.2–q13.1 −8202A → G rs11697
PDE4D 5q12 C→ T rs9662
ABCA1 9q22–q31 −14C → T rs1800
Odds ratio (OR) and 95% conﬁdence interval (CI) were calculated with genotypes (GG ve
polymorphisms.individuals with obesity than in controls. Similar differences, with the
exception of the serum concentration of total cholesterol, were
observed between individuals with obesity and controls in subject
panel B.
Polymorphisms associated with obesity
Comparisons of genotype distributions or allele frequencies for
the 95 selected polymorphisms with the χ2 test revealed that the
2677G→ A/T (Ala893Thr/Ser) polymorphism (rs2032582) of the ATP-
binding cassette, subfamily B, member 1 gene (ABCB1), the −3459A→
G polymorphism (rs3092952) of the CD40 ligand gene (CD40LG), the
6986A → G polymorphism (rs776746) in intron 3 of the cytochrome
P450, subfamily IIIA, polypeptide 5 gene (CYP3A5), the −8202A →
G polymorphism (rs11697325) of thematrixmetalloproteinase-9 gene
(MMP9), the C→ T polymorphism (rs966221) of the phosphodiester-
ase 4D, cAMP-speciﬁc gene (PDE4D), and the −14C→ T polymorphism
(rs1800977) of the ATP-binding cassette, subfamily A, member 1 gene
(ABCA1) were signiﬁcantly (pb0.05) related to the prevalence of
obesity in subject panel A (Table 2). Application of Bonferroni's
correction (pb0.05/95=0.0005) for statistical signiﬁcance of associa-
tion to avoid type I error in the multiple comparisons of genotypes
revealed only the 2677G → A/T polymorphism of ABCB1 to be
signiﬁcantly (p=0.0003) associated with the prevalence of obesity.
The relation of this polymorphism to obesity was examined further
by multivariable logistic regression analysis. Given that the 2677G→
A/T (Ala893Thr/Ser) polymorphism of ABCB1 is triallelic, we deﬁned
the G allele as the wild-type allele and the A and T alleles as the
variant alleles, as previously described [18]. Multivariable logistic
regression analysis with adjustment for age, sex, and smoking status
revealed that the 2677G → A/T polymorphism of ABCB1 (dominant
and additive 1 models) was signiﬁcantly (pb0.05) associated with the
prevalence of obesity (Table 3).
To validate this association, we examined the relation of the
2677G → A/T polymorphism of ABCB1 to obesity in subject panel B.
The χ2 test revealed that this polymorphismwas signiﬁcantly (pb0.05)
related to the prevalence of obesity (Table 2). Multivariable logistic
regression analysiswith adjustment for age, sex, and smoking status also
revealed that this polymorphism (dominant and additive 1models)was
signiﬁcantly (pb0.05) associated with the prevalence of obesity
(Table 3). We also examined the relation of this polymorphism of
ABCB1 to obesity for men and women separately in combined subject
panels A and B by theχ2 test. The 2677G→A/T polymorphismof ABCB1
was signiﬁcantly related to obesity both in men (p=0.0008) and in
women (p=0.003). The genotype distributions for the six polymor-
phisms related to obesity in subject panel A were in Hardy–Weinberg
equilibrium in control subjects of each panel.
Relation of genotypes associated with obesity to BMI
The relation between BMI and genotypes associated with obesity
was investigated in combined groups A and B as well as for men andd replication of the results in subject panel B
Panel A Panel B
No. p OR (95% CI) p OR (95% CI)
582 0.0003 1.28 (1.09–1.53) 0.0366 1.53 (1.08–2.16)
952 0.0094 0.76 (0.64–0.91) 0.4871 1.04 (0.74–1.45)
6 0.0122 1.12 (1.05–1.30) 0.7901 0.97 (0.80–1.18)
325 0.0150 1.02 (0.83–1.25) 0.6123 1.11 (0.72–1.72)
21 0.0393 0.85 (0.74–0.96) 0.0497 1.16 (0.96–1.41)
977 0.0447 0.87 (0.78–0.97) 0.6246 0.99 (0.80–1.23)
rsus others) for the ABCB1 polymorphism and with allele frequencies for the other
Table 3
Multivariate logistic regression analysis for subject panels A and B of polymorphisms related to obesity in subject panel A by the χ2 test
Genesymbol Dominant Recessive Additive 1 Additive 2Polymorphism
p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95%CI)
Subject panel A
ABCB1 2677G → A/T 0.0022 1.31 (1.10–1.56) 0.0673 0.0001 1.44 (1.20–1.73) 0.1888
CD40LG –3459A → G 0.0084 0.78 (0.64–0.94) 0.0150 0.71 (0.54–0.93) 0.1934 0.0141 0.72 (0.54–0.93)
CYP3A5 6986A → G in intron 3 0.4142 0.0017 1.24 (1.08–1.42) 0.9161 0.1664
MMP9 –8202A → G 0.5483 0.8396 0.5474 0.5484
PDE4D C→ T 0.1709 0.0277 0.85 (0.73–0.98) 0.3741 0.1276
ABCA1 –14C → T 0.0110 0.84 (0.73–0.96) 0.2394 0.0220 0.85 (0.74–0.98) 0.1064
Subject panel B
ABCB1 2677G → A/T 0.0458 1.42 (1.01–2.03) 0.7798 0.0231 1.54 (1.07–2.24) 0.1828
CD40LG –3459A → G 0.8902 0.4216 0.1398 0.6616
CYP3A5 6986A → G in intron 3 0.7324 0.7258 0.8045 0.6949
MMP9 –8202A → G 0.7252 0.7252
PDE4D C→ T 0.2540 0.3944 0.2006 0.2753
ABCA1 –14C → T 0.9027 0.6002 0.7871 0.6371
OR, odds ratio; CI, conﬁdence interval. Multivariable logistic regression analysis was performed with adjustment for age, sex, and smoking status.
514 S. Ichihara et al. / Genomics 91 (2008) 512–516women separately. BMI was signiﬁcantly greater in individuals with
the variant A or T alleles than in those with the GG genotype of ABCB1
among all subjects (Table 4). This relation was also apparent in men
but not in women. Furthermore, BMI was signiﬁcantly (p=0.01)
greater for individuals with the variant T allele of this polymorphism
than for those with the GG genotype in the combined subject panels A
and B (Table 4).
Discussion
We have examined the relation of 95 polymorphisms in 67
candidate genes to obesity in 5448 individuals in two independent
subject panels. Our large-scale association study revealed that the
2677G → A/T polymorphism of ABCB1 was signiﬁcantly associated
with the prevalence of obesity in both subject panels. This poly-
morphism was signiﬁcantly related to obesity both in men and in
women among combined subject panels A and B by the χ2 test.
ABCB1
Human P-glycoprotein, a 170-kDa transmembrane glycoprotein
encoded by ABCB1, also known as the multidrug resistance 1 gene
(MDR1), is a member of the ABC transporter family. It functions as
an important membrane-bound transporter that extrudes a wide
range of structurally and mechanistically unrelated drugs out of
cells [19]. A systematic screen for ABCB1 polymorphisms revealed
several single-nucleotide polymorphisms in this gene [20]. Among the
polymorphisms of ABCB1, the functional signiﬁcance of the 2677G→
A/T (Ala893Thr/Ser) polymorphism in exon 21 has remained unclear.
Like many other triallelic single-nucleotide polymorphisms, this
polymorphism of ABCB1 was originally described as diallelic becauseTable 4
Relation of BMI (kg/m2) to genotypes of the 2677G→ A/T polymorphism of ABCB1 for all
subjects as well as for men and women separately
Subjects GG Others T allele A allele AT
Total 23.22±3.25 23.51±3.31 23.52±3.32 23.39±3.29 23.30±3.29
p=0.0122 p=0.0100 p=0.2025 p=0.6291
Men 23.20±3.05 23.49±3.13 23.44±3.15 23.50±3.00 23.27±2.92
p=0.0374 p=0.1009 p=0.0520 p=0.7305
Women 23.26±3.50 23.53±3.54 23.64±3.54 23.24±3.62 23.35±3.73
p=0.1452 p=0.0444 p=0.9230 p=0.7381
Others, individuals with GT, GA, TT, AA, or AT genotype. T allele, individuals with GT, TT,
or AT genotype. A allele, individuals with GA, AA, or AT genotype. Data are means±SD.genotyping methods failed to reveal the existence of the rare third (A)
allele [21]. Moreover, the allele frequencies for this triallelic
polymorphism of ABCB1 have been found to differ among ethnic
groups and to be ethnically related [22]. The allele frequencies of the
polymorphism in control subjects of the present study were similar to
those of healthy Japanese individuals in previous studies [23,24].
The 2677G (893Ala) allele of the 2677G → A/T (Ala893Thr/Ser)
polymorphism of ABCB1 was shown to be associated with inﬂamma-
tory bowel disease by both case–control analysis and the pedigree
transmission disequilibrium test [25]. Furthermore, individuals
with the variant alleles of this polymorphism had a higher plas-
ma renin activity than did those with the 2677G (893Ala) allele
[26]. This polymorphism has also been shown to affect the function of
P-glycoprotein [18]. Studies have thus suggested that the polymorph-
ism is associated with altered transporter activity or gene expres-
sion [27,28]. The functional relevance of this polymorphism in vivo
was assessed with a drug substrate of P-glycoprotein as a probe
of transporter activity. The variants of ABCB1 were associated
with differences in drug substrate levels, suggesting that the activity
of P-glycoprotein was increased in individuals with the variant alleles
[27]. Hereditary variation in the genes formembrane transporters such
as P-glycoprotein might explain, at least in part, differences among
individuals in the pharmacokinetics of and the clinical response to a
variety of drugs. Whereas the role of P-glycoprotein in the transport
andmetabolism of drugs has beenwell characterized, little is known of
the physiological functions of this protein. We have now shown that
the 2677G→ A/T polymorphism of ABCB1was signiﬁcantly associated
with the prevalence of obesity. Given that the ABC transporter family
mediates the transport of various substrates—including sugars, lipids,
amino acids, and steroids as well as chemotherapeutic agents—across
cell membranes, polymorphisms of ABCB1 might affect the morbidity
of diseases such as obesity that are associated with profound changes
in the levels of hormones or other physiological molecules.
Different effects of the ABCB1 polymorphism on body fat in men and
women
The distribution of body fat differs between men and women. Men
often have upper body obesity, whereas peripheral obesity is most
common in women. Gene polymorphisms might therefore have dif-
ferent effects on body fat between men and women. The −3826A →
G polymorphism of the uncoupling protein 1 gene (UCP1), for example,
was associated with obesity only in women [29]. The Gln27Glu
polymorphism of ADRB2 was also shown to be associated with obesity
in women but not in men of a Swedish population [30]. In contrast,
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associated with BMI or waist circumference only in men [31]. These
studies indicate that obesity susceptibility genes may differ between
men and women. In the present study, the 2677G→ A/T polymorphism
of ABCB1 was signiﬁcantly related to obesity both in men (p=0.0008)
and inwomen (p=0.003) amongcombined subjectpanelsA andBby the
χ2 test. However, genotypes forABCB1were associatedwith BMI inmen
but not in women, suggesting that the effects of this polymorphism on
BMI might be modiﬁed by sex hormones or environmental factors.
Further studies are needed to determine the functional relevance of the
2677G→ A/T polymorphism of ABCB1 to obesity.
Study limitations
In the present study, obesity was deﬁned as a BMI of ≥25 kg/m2.
Caution is warranted, however, in the diagnosis of obesity on the basis
of BMI alone because BMI is not a discrete phenotype. Individuals with
a BMI of ≥30 or ≥25 kg/m2 are considered obese and overweight,
respectively, according to the WHO criteria. On the basis of the recent
recognition of a need to revise BMI criteria for obesity in Japanese and
other Asian populations, we set the cutoff point for obesity as a BMI of
≥25 kg/m2 in the present study. It is also possible that the poly-
morphism associated with obesity in the present study is in linkage
disequilibriumwith polymorphisms of the same gene or other nearby
genes that are actually responsible for this condition. Furthermore, the
relevance of the identiﬁed polymorphism to protein structure or
functionwas not determined in the present study. Further studies will
be required to investigate the effects of the identiﬁed polymorphism
of the expression or activity of P-glycoprotein in vivo and in vitro
and to clarify the role of P-glycoprotein in lipid and adipose tissue
metabolism.
Conclusion
Our results show that ABCB1 is a susceptibility locus for obesity in
Japanese men. Determination of genotype for ABCB1 may prove
informative in the assessment of genetic risk for obesity.
Materials and methods
Study population
A total of 5448 individuals from two independent populations were examined.
Subject panel A comprised 4252 individuals who either visited outpatient clinics of or
were admitted to the participating hospitals (Gifu Prefectural General Medical Center
and Gifu Prefectural Tajimi Hospital in Gifu Prefecture, Japan, and Hirosaki University
Hospital, Reimeikyo Rehabilitation Hospital, and Hirosaki Stroke Center in Aomori
Prefecture, Japan) betweenOctober 2002 andMarch 2007 because of various symptoms
or for an annual health checkup. Subject panel B comprised 1196 community-dwelling
elderly individuals recruited to a population-based prospective cohort study of aging
and age-related diseases in Gunma Prefecture, Japan. On the basis of the recent recog-
nition of a need to revise BMI criteria for obesity in Japanese and other Asian populations
[32], obesity was deﬁned as a BMI of ≥25 kg/m2. A total of 1308 individuals (764 men,
544 women) in subject panel A were classiﬁed as obese; control subjects comprised
2944 individuals (1778 men, 1166 women) who visited the outpatient clinics of
participating hospitals for an annual health checkup and who had a BMI of b25 kg/m2.
Among subject panel B, 312 individuals (140 men, 172 women) were classiﬁed as obese
and 884 individuals (438 men, 446 women) were classiﬁed as controls. The study
protocol complied with the Declaration of Helsinki and was approved by the
Committees on the Ethics of Human Research of Mie University Graduate School of
Medicine, Hirosaki University Graduate School of Medicine, Gifu International Institute
of Biotechnology, Tokyo Metropolitan Institute of Gerontology, and participating
hospitals, and written informed consent was obtained from each participant.
Selection of polymorphisms
Our aimwas to identify genes associatedwith obesity in the Japanese population in a
case–control association study by examining the relation of one to ﬁve polymorphisms
of each candidate gene to this condition. With the use of public databases [PubMed
(NCBI) and Online Mendelian Inheritance in Man (NCBI)], we selected 67 candidate
genes that have been characterized andwere suggested to be associatedwith obesity on
the basis of a comprehensive overview of lipid and adipose tissue metabolism, insulinand glucose metabolism, and other metabolic factors as well as of regulation of
endocrine function, inﬂammation, and monocyte–macrophage, lymphocyte, and
leukocyte biology. We further selected 95 polymorphisms of these genes that had
been described in published studies by searching PubMed and single-nucleotide poly-
morphism databases [dbSNP (NCBI) and Japanese SNP database (JSNP)]. Polymorphisms
shown to be most related to phenotypes and to be located in the promoter region or
exons, and which therefore might be expected to result in changes in the function or
expression of the encoded proteins, were chosen (Supplementary Table 1). Wild-type
and variant alleles of the polymorphisms were determined from the original sources.
None of the selected polymorphisms had been examined in our previous study [33].
Genotyping of polymorphisms
Venous blood (7 ml) was collected into tubes containing 50 mmol/L EDTA (disodium
salt), and genomic DNAwas isolatedwith a kit (Genomix; Talent, Trieste, Italy). Genotypes
of the 95 polymorphisms were determined at G&G Science (Fukushima, Japan) by a
method combining the polymerase chain reaction and sequence-speciﬁc oligonucleotide
probes with suspension array technology (Luminex 100; Luminex, Austin, TX, USA).
Detailed methodology for genotyping was described previously [34]. To conﬁrm the
accuracy of genotyping by suspension array technology in the present study, we selected
DNA samples from 23 subjects and genotyped the 95 polymorphisms by chip-based
matrix-assisted laser desorption-ionization time-of-ﬂight mass spectrometry [35]. Only 4
of the 2185 genotypes determined by this approach differed from those identiﬁed by
suspension array technology. We then determined these 4 discrepant genotypes by DNA
sequencing with a ﬂuorescence-based automated DNA sequencer (Applied Biosystems,
Foster City, CA, USA) after ampliﬁcation and cloning of the polymorphic regions. All four
genotypes determined by DNA sequencing were identical to those determined by
suspension array technology, demonstrating the accuracy of the latter approach in the
present study. The genotype distributions and allele frequencies for the 95polymorphisms
in subject panels A and B are shown in Supplementary Table 2.
Statistical analysis
Quantitative data were compared between subjects with obesity and controls by the
unpaired Student t test. Categorical data were compared by theχ2 test. Allele frequencies
were estimated by the gene-counting method, and the χ2 test was used to identify
departure from Hardy–Weinberg equilibrium. In the initial screen, the genotype
distributions for each autosomal polymorphism in subject panel A were compared
between subjects with obesity and controls with the χ2 test (3×2); for polymorphisms
located on the X chromosome, allele frequencies were compared with the χ2 test (2×2).
Polymorphisms found to be related (pb0.05) to obesity by the χ2 test were examined by
multivariable logistic regression analysis with adjustment for covariates, with obesity as a
dependent variable and independent variables including age, sex (0, woman; 1, man),
smoking status (0, nonsmoker; 1, smoker), and genotype of each polymorphism. Each
genotypewas assessed according to dominant, recessive, and two additive (additive 1 and
2) geneticmodels, and thep value, odds ratio, and95% conﬁdence intervalwere calculated.
Each genetic model comprised two groups: the combined group of variant homozygotes
and heterozygotes versus wild-type homozygotes for the dominant model; variant
homozygotes versus the combined group ofwild-typehomozygotes andheterozygotes for
the recessive model; heterozygotes versus wild-type homozygotes for the additive 1
model; and variant homozygotes versus wild-type homozygotes for the additive 2 model.
A p value of b0.05 was considered statistically signiﬁcant. Statistical analyses were
performed with JMP version 5.1 software (SAS Institute, Cary, NC, USA).
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